Your end-to-end CDMO partner
for your viral vector projects

From development to market,
ABL provides GMP viral vectors, contributing to the success
of our clients’ immunotherapy and gene therapy innovations.

We are a pure play CDMO, specialized in development and GMP manufacturing of viral vectors.

We can help guide you through your process development, tech transfer, validation and QA, all the way to a complete CMC package and documentation

Our European sites are GMP certified

Vaccines

Vaccines

Oncolytic (Virotherapies)

Oncolytic (Virotherapies)

Other Immunotherapies

Other Immunotherapies

ABL

An Institut Mérieux Company

Institut Mérieux

We have been a pioneer in developing and producing viral vectors since 1994.

We are grounded in the Mérieux family’s legacy of biology and vaccine expertise since 1897.

We are a pure CDMO player contributing to the success of your immunotherapy and gene therapy innovations.

  • 1994
    first viral vector facility in Europe
  • 4
    facilities
    (France & USA)
  • ~320
    employees
  • >25
    years of experience
    in viral vectors (manufacturing)
  • Fill & finish up to
    10,000
    vials/batch

ABL
Your solution provider

Please accept marketing cookies to watch this video.

Services